 |
|
Comparison of efficacies of once-daily dose multimatrix mesalazine and multiple-dose mesalazine for the maintenance of remission in ulcerative colitis: a randomized, double-blind study
Haruhiko Ogata, Akihiro Ohori, Haruo Nishino, Seiichi Mizushima, Atsushi Hagino, Toshifumi Hibi
Intest Res. 2017;15(3):358-367. Published online 2017 Jun 12 DOI: https://doi.org/10.5217/ir.2017.15.3.358
|
|
Citations to this article as recorded by
 A review on the current status and definitions of activity indices in inflammatory bowel disease: how to use indices for precise evaluation
Masahiro Kishi, Fumihito Hirai, Noritaka Takatsu, Takashi Hisabe, Yasumichi Takada, Tsuyoshi Beppu, Ken Takeuchi, Makoto Naganuma, Kazuo Ohtsuka, Kenji Watanabe, Takayuki Matsumoto, Motohiro Esaki, Kazutaka Koganei, Akira Sugita, Keisuke Hata, Kitarou Fut
Journal of Gastroenterology.2022; 57(4): 246. CrossRef Inflammatory Bowel Disease – Non-biological treatment
Fernando Magro, Gonçalo Cordeiro, Andreia Martins Dias, Maria Manuela Estevinho
Pharmacological Research.2020; 160: 105075. CrossRef Systematic review: safety of mesalazine in ulcerative colitis
P. Sehgal, J.‐F. Colombel, A. Aboubakr, N. Narula
Alimentary Pharmacology & Therapeutics.2018; 47(12): 1597. CrossRef How to Optimally Use Currently Available Drugs in a Therapeutic Algorithm?
You Sun Kim
The Korean Journal of Gastroenterology.2018; 71(2): 74. CrossRef
|